Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Icatibant Acetate

FDA-approved product (injectable, subcutaneous), marketed as Firazyr, Icatibant Acetate.

Registered studies
33
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Icatibant Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Angioedema
  • Hereditary angioedema

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Drugs used in hereditary angioedema
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

33registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Icatibant Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Icatibant Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks

    NCT07009262 · start 2025-04-21

    Registered record
    Registry ID
    NCT07009262
    Conditions
    Hereditary Angioedema
    Interventions
    Inapplicable
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2025-04-21
    Completion
    2025-11-25
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Angioedema
    InterventionInapplicable
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns in Korean People

    NCT06587464 · start 2024-10-16

    Registered record
    Registry ID
    NCT06587464
    Conditions
    Hereditary Angioedema (HAE)
    Interventions
    No Intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-10-16
    Completion
    2024-12-18
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Angioedema (HAE)
    InterventionNo Intervention
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema

    NCT07290855 · start 2024-09-27

    Registered record
    Registry ID
    NCT07290855
    Conditions
    Bradykinin-mediated Angioedema; Hereditary Angioedema (HAE)
    Interventions
    Icatibant Injection (Icanticure®)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-09-27
    Completion
    2025-09-26
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBradykinin-mediated Angioedema; Hereditary Angioedema (HAE)
    InterventionIcatibant Injection (Icanticure®)
    PhasePhase 4
    Registry statusCompleted

  • A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China

    NCT06346899 · start 2024-07-20

    Registered record
    Registry ID
    NCT06346899
    Conditions
    Hereditary Angioedema (HAE)
    Interventions
    No intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-07-20
    Completion
    2025-07-31
    Enrolment
    115

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Angioedema (HAE)
    InterventionNo intervention
    PhaseNot recorded
    Registry statusCompleted

  • Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor

    NCT05834777 · start 2023-12-11

    Registered record
    Registry ID
    NCT05834777
    Conditions
    Intradialytic Hypotension
    Interventions
    Icatibant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-12-11
    Completion
    2026-11-01
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntradialytic Hypotension
    InterventionIcatibant; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home

    NCT05489640 · start 2022-11-18

    Registered record
    Registry ID
    NCT05489640
    Conditions
    Hereditary Angioedema (HAE)
    Interventions
    No Intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-11-18
    Completion
    2024-07-17
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Angioedema (HAE)
    InterventionNo Intervention
    PhaseNot recorded
    Registry statusCompleted

  • A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema

    NCT05509569 · start 2022-08-24

    Registered record
    Registry ID
    NCT05509569
    Conditions
    Hereditary Angioedema (HAE)
    Interventions
    Icatibant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-08-24
    Completion
    2026-07-17
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Angioedema (HAE)
    InterventionIcatibant
    PhaseNot recorded
    Registry statusCompleted

  • Inhibition of Bradykinin in COVID-19 Infection With Icatibant

    NCT05407597 · start 2022-05-16

    Registered record
    Registry ID
    NCT05407597
    Conditions
    SARS CoV 2 Infection
    Interventions
    Icatibant; 0.9% Sodium Chloride Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2022-05-16
    Completion
    2023-07-07
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSARS CoV 2 Infection
    InterventionIcatibant; 0.9% Sodium Chloride Injection
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection

    NCT04978051 · start 2021-04-12

    Registered record
    Registry ID
    NCT04978051
    Conditions
    COVID-19 Pneumonia
    Interventions
    Firazyr; SoC
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-04-12
    Completion
    2022-03-17
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19 Pneumonia
    InterventionFirazyr; SoC
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).

    NCT05010876 · start 2021-02-04

    Registered record
    Registry ID
    NCT05010876
    Conditions
    Covid19
    Interventions
    C1 Inhibitor Human; Icatibant Injection; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-02-04
    Completion
    2021-06-21
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19
    InterventionC1 Inhibitor Human; Icatibant Injection; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema

    NCT04654351 · start 2021-01-15

    Registered record
    Registry ID
    NCT04654351
    Conditions
    Hereditary Angioedema
    Interventions
    TAK-667
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-01-15
    Completion
    2021-07-27
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Angioedema
    InterventionTAK-667
    PhasePhase 3
    Registry statusCompleted

  • I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

    NCT04488081 · start 2020-07-31

    Registered record
    Registry ID
    NCT04488081
    Conditions
    COVID-19
    Interventions
    Remdesivir; Imatinib Mesylate; Dexamethasone; Cenicriviroc; Icatibant; Apremilast; dornase alfa; Celecoxib; Famotidine; IC14; Aviptadil; narsoplimab; Cyproheptadine; Cyclosporine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-07-31
    Completion
    2030-07-31
    Enrolment
    1,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionRemdesivir; Imatinib Mesylate; Dexamethasone; Cenicriviroc +10 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2

    NCT04113109 · start 2019-11-01

    Registered record
    Registry ID
    NCT04113109
    Conditions
    Heart Failure
    Interventions
    LCZ 696; Icatibant; placebo; Para-aminohippurate; Iohexol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-11-01
    Completion
    2025-07-30
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionLCZ 696; Icatibant; placebo; Para-aminohippurate +1 more
    PhasePhase 4
    Registry statusCompleted

  • FIRAZYR General Drug Use-Results Survey (Japan)

    NCT04057131 · start 2018-11-20

    Registered record
    Registry ID
    NCT04057131
    Conditions
    Hereditary Angioedema (HAE)
    Interventions
    Firazyr
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-11-20
    Completion
    2024-07-29
    Enrolment
    179

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Angioedema (HAE)
    InterventionFirazyr
    PhaseNot recorded
    Registry statusCompleted

  • Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2

    NCT03005184 · start 2017-09

    Registered record
    Registry ID
    NCT03005184
    Conditions
    Heart Failure NYHA Class I; Heart Failure NYHA Class II; Heart Failure NYHA Class III
    Interventions
    Valsartan 80 mg bid; Enalapril 10 mg bid; Sacubitril-Valsartan 200 mg bid; Icatibant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2017-09
    Completion
    2020-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure NYHA Class I; Heart Failure NYHA Class II; Heart Failure NYHA Class III
    InterventionValsartan 80 mg bid; Enalapril 10 mg bid; Sacubitril-Valsartan 200 mg bid; Icatibant +1 more
    PhasePhase 2
    Registry statusWithdrawn